• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (22)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in this journal  Topic Collections  • Neurology  • Lewy Body Disease  • Movement Disorders  • Parkinson Disease/ Parkinsonian Disorders  • Psychiatry  • Anxiety Disorders  • Review  • Diagnosis  • Gastrointestinal Diseases  • Hematology/ Hematologic Malignancies  • Anemias  • Alert me on articles by topic  Social Bookmarking   What's this?

Rodolfo Savica, MD, MSc; Walter A. Rocca, MD, MPH; J. Eric Ahlskog, PhD, MD

Arch Neurol. 2010;67(7):798-801. doi:10.1001/archneurol.2010.135

There is convincing evidence that the Parkinson disease neurodegenerative process begins many years before the onset of motor manifestations. Initial estimates based on nigral neuropathological findings or striatal dopamine imaging suggested a 5- to 6-year preclinical period. However, more recent evidence of Lewy body pathology in other neuronal populations preceding nigral involvement suggests that the preclinical phase may be much longer. Epidemiologic studies of nonmotor manifestations, such as constipation, anxiety disorders, rapid eye movement sleep behavior disorder (RBD), and anemia, suggest that the preclinical period extends at least 20 years before the motor manifestations. Olfactory impairment and depression may also precede the onset of motor manifestations; however, the lag time may be shorter. Recognition of a nonmotor preclinical phase spanning 20 or more years should guide the search for predictive biomarkers and the identification of risk or protective factors for Parkinson disease.

Author Affiliations: Division of Epidemiology, Department of Health Sciences Research, (Drs Savica and Rocca), and Department of Neurology (Drs Savica, Rocca, and Ahlskog), College of Medicine, Mayo Clinic, Rochester, Minnesota.

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Prospective Research on Parkinson Nonmotor Symptoms
Honglei Chen, Xiang Gao, and Alberto Ascherio
Arch Neurol. 2011;68(1):137.
EXTRACT | FULL TEXT  

Prospective Research on Parkinson Nonmotor Symptoms—Reply
Rodolfo Savica, Walter A. Rocca, and J. Eric Ahlskog
Arch Neurol. 2011;68(1):137-138.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Parkinson disease: The enteric nervous system spills its guts
Derkinderen et al.
Neurology 2011;77:1761-1767.
ABSTRACT | FULL TEXT  

Management of sexual dysfunction in Parkinson's disease
Bronner and Vodusek
Therapeutic Advances in Neurological Disorders 2011;4:375-383.
ABSTRACT  

Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection
Srinivasan et al.
Therapeutic Advances in Neurological Disorders 2011;4:297-317.
ABSTRACT  

Prospective Research on Parkinson Nonmotor Symptoms
Chen et al.
Arch Neurol 2011;68:137-137.
FULL TEXT  

Prospective Research on Parkinson Nonmotor Symptoms--Reply
Savica et al.
Arch Neurol 2011;68:137-138.
FULL TEXT  

Current understanding and management of Parkinson disease: Five new things
Morley and Hurtig
Neurology 2010;75:S9-S15.
FULL TEXT  

PGC-1{alpha}, A Potential Therapeutic Target for Early Intervention in Parkinson's Disease
Zheng et al.
Sci Transl Med 2010;2:52ra73-52ra73.
ABSTRACT | FULL TEXT